About
Contact & Profiles
A5008537151
Research Areas
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
Hacettepe University
2023
Ponatinib is a third-generation tyrosine kinase inhibitor with potent efficacy in the treatment of acute and chronic leukemia. Despite having an effective sustained activity all BCR-ABL1 mutations, it may cause cardiovascular adverse effects. Here we report 56-year-old male patient Chronic myeloid leukemia no prior cardiac disorder who developed heart failure under ponatinib treatment. Guideline-recommended medical for was initiated. Coronary angiography to exclude ischemic disease revealed...
10.51271/jchor-0023
article
EN
cc-by-nc-nd
Journal of Current Hematology & Oncology Research
2023-11-30
Coming Soon ...